Company profile: Serina Therapeutics
1.1 - Company Overview
Company description
- Provider of proprietary polymer-based drug delivery and therapeutics, including the POZ Platform for programmable, targeted, continuous small-molecule delivery (IV/SC/IM); SER-252 for advanced Parkinson’s Disease; CNS small-molecule conjugates; POZ-lipid LNPs for mRNA immunology; and ADCs that increase DAR to improve efficacy, addressing cancer, inflammation, pain and metabolic disorders.
Products and services
- POZ Platform™: A custom-engineered polymer technology that architects programmable, targeted small-molecule delivery, enabling continuous drug administration via intravenous, subcutaneous, or intramuscular routes
- SER-252: An investigational, twice-weekly subcutaneous apomorphine injection for advanced Parkinson’s Disease that reduces ‘OFF’ time without adverse skin reactions, anticipated to enter clinical trials in 2025
- Antibody-Drug Conjugates (ADCs): An oncology-optimized technology that boosts efficacy against low-density targets by elevating the Drug Antibody Ratio (DAR) of cancer-killing cytotoxic payloads
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Serina Therapeutics
Afferent Pharmaceuticals
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical therapies for chronic pain, developing medicines that target P2X3 receptors in nerve fibers. Its lead compound, AF-219, has completed two Phase 1 clinical studies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Afferent Pharmaceuticals company profile →
Neurofluidics
HQ: United States
Website
- Description: Provider of organs-on-chip and microfluidic medical devices that reproduce in vitro neuronal networks up to connectome-on-chip, enabling study of human organ physiology, drug effects, and molecular and functional mechanisms on neuronal circuits. Offerings include MEA-integrated devices for recording neural activity (developed with Axion BioSystems), UpLink software, and models such as innervated skin, pain-on-chip, and DuaLink for chemotherapy studies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Neurofluidics company profile →
Tissuemed
HQ: United Kingdom
Website
- Description: Provider of tissue-based therapeutic devices and surgical bioadhesive films, including the first tissue heart valve to gain regulatory approval in Europe. Specializes in adhesive films to prevent air, blood and fluid leaks encountered in surgery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tissuemed company profile →
Clairvoyant Therapeutics
HQ: Canada
Website
- Description: Provider of psilocybin-based therapy solutions for Alcohol Use Disorder, including a 24-week Phase 2b clinical trial with synthetic psilocybin and two dosing sessions, a 35-hour therapist training program to support participants, and a therapist adherence monitoring program to monitor adherence to trial protocol and ethics, pursuing a speed-to-market clinical strategy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Clairvoyant Therapeutics company profile →
PhysioSonics
HQ: United States
Website
- Description: Provider of ultrasound imaging technology to monitor blood flow in the brain; development-stage device company based in Washington.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PhysioSonics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Serina Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Serina Therapeutics
2.2 - Growth funds investing in similar companies to Serina Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Serina Therapeutics
4.2 - Public trading comparable groups for Serina Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →